Lybalvi
Active Ingredient(s): Olanzapine + Samidorphan L-malateFDA Approved: * May 28, 2021
Pharm Company: * ALKERMES INC
Category: Antipsychotic
Olanzapine/samidorphan (OLZ/SAM), sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder.[1] It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist.[1][2][3] Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.[4][5]... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.